[go: up one dir, main page]

MX2017009793A - Agentes de union de la superfamilia del receptor de factor de necrosis tumoral y usos de los mismos. - Google Patents

Agentes de union de la superfamilia del receptor de factor de necrosis tumoral y usos de los mismos.

Info

Publication number
MX2017009793A
MX2017009793A MX2017009793A MX2017009793A MX2017009793A MX 2017009793 A MX2017009793 A MX 2017009793A MX 2017009793 A MX2017009793 A MX 2017009793A MX 2017009793 A MX2017009793 A MX 2017009793A MX 2017009793 A MX2017009793 A MX 2017009793A
Authority
MX
Mexico
Prior art keywords
agents
polypeptides
tnfrsf
binding agents
disclosed
Prior art date
Application number
MX2017009793A
Other languages
English (en)
Inventor
L Gurney Austin
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2017009793A publication Critical patent/MX2017009793A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen polipéptidos y agentes que se unen a una proteína de la superfamilia de receptor de TNF, particularmente agentes que se unen específicamente a GITR, OX40 o CD40. Los polipéptidos o agentes pueden incluir polipéptidos de fusión, particularmente polipéptidos que comprenden GITRL, OX40L o CD40L y/o agentes biespecíficos. También se describen métodos de uso de los polipéptidos o agentes para inducir y/o incrementar la respuesta inmunitaria así como métodos para el tratamiento de enfermedades como por ejemplo cáncer.
MX2017009793A 2015-02-03 2016-02-03 Agentes de union de la superfamilia del receptor de factor de necrosis tumoral y usos de los mismos. MX2017009793A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562111404P 2015-02-03 2015-02-03
US201562153272P 2015-04-27 2015-04-27
US201562154008P 2015-04-28 2015-04-28
US201562218956P 2015-09-15 2015-09-15
US201562259129P 2015-11-24 2015-11-24
PCT/US2016/016306 WO2016126781A1 (en) 2015-02-03 2016-02-03 Tnfrsf-binding agents and uses thereof

Publications (1)

Publication Number Publication Date
MX2017009793A true MX2017009793A (es) 2017-10-27

Family

ID=56564627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009793A MX2017009793A (es) 2015-02-03 2016-02-03 Agentes de union de la superfamilia del receptor de factor de necrosis tumoral y usos de los mismos.

Country Status (18)

Country Link
US (2) US9724390B2 (es)
EP (1) EP3253890A4 (es)
JP (1) JP2018508233A (es)
KR (1) KR20170108073A (es)
CN (2) CN107406878A (es)
AU (1) AU2016215394A1 (es)
BR (1) BR112017016705A2 (es)
CA (1) CA2975596A1 (es)
CO (1) CO2017008047A2 (es)
EA (1) EA201791313A1 (es)
HK (1) HK1243741A1 (es)
IL (1) IL253433A0 (es)
MA (1) MA41460A (es)
MX (1) MX2017009793A (es)
PH (1) PH12017501372A1 (es)
SG (1) SG11201706268XA (es)
TW (1) TW201643184A (es)
WO (1) WO2016126781A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150425T1 (hr) * 2008-07-21 2015-06-05 Apogenix Gmbh Tnf sf jednolanäśane molekule
CN107892719B (zh) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
AU2014291961B2 (en) 2013-07-19 2018-09-27 Centre Hospitalier Regional Universitaire De Montpellier Targeted modified TNF family members
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
JP6744318B2 (ja) * 2015-02-06 2020-08-26 ヒート バイオロジクス，インコーポレイテッド ワクチンおよび共刺激分子を共発現するベクター
JP6826055B2 (ja) 2015-03-13 2021-02-03 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
RU2766200C1 (ru) 2015-10-01 2022-02-09 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
MX2018013762A (es) * 2016-05-13 2019-03-28 Medimmune Llc Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.
MX2018015853A (es) 2016-07-14 2019-08-21 Genmab As Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
IL268346B2 (en) 2017-02-06 2024-08-01 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
WO2018151820A1 (en) * 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN118184797A (zh) 2017-02-27 2024-06-14 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
CA3054132A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Csf1r-based chimeric proteins
KR102745835B1 (ko) 2017-02-27 2024-12-24 샤턱 랩스 인코포레이티드 Tigit- 및 light-기반 키메라 단백질
WO2018160572A1 (en) * 2017-02-28 2018-09-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising gitr-binding agents
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
CN113831417B (zh) * 2017-05-08 2024-10-01 上海津曼特生物科技有限公司 双特异性重组蛋白及其应用
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
US11377490B2 (en) * 2017-05-31 2022-07-05 Sichuan Clover Biopharmaceuticals, Inc Method for treating cancer using disulfide-linked trimeric 4-1BBL
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
AU2018281337B2 (en) 2017-06-06 2022-08-25 Relinia, Inc. Single-chain TNF receptor 2 agonist fusion proteins
KR102371420B1 (ko) * 2017-06-27 2022-03-08 (주)아모레퍼시픽 Tnfsf14 단백질을 포함하는 미백용 조성물
WO2019032945A1 (en) * 2017-08-10 2019-02-14 Oncomed Pharmaceuticals, Inc. CD40 BINDING AGENT AND USES THEREOF
CN118852460A (zh) * 2017-12-28 2024-10-29 尤利乌斯·马克西米利安维尔茨堡大学 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
KR102763158B1 (ko) 2018-04-25 2025-02-04 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
WO2019237383A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 用于人 tnfsf18 基因编辑的修饰载体、其制备方法及应用
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
CN111454364B (zh) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 结合cd40的抗体及其用途
CN113811547B (zh) * 2019-03-27 2024-06-25 国家医疗保健研究所 具有cd40激活特性的重组蛋白
EP3986920B1 (en) 2019-06-24 2025-04-16 Universität Stuttgart Tnfr2 agonists with improved stability
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
US20230212260A1 (en) * 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
GB202007321D0 (en) * 2020-05-18 2020-07-01 Inst De Medicina Molecular Joaeo Lobo Antunes T cells
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
TW202302625A (zh) * 2021-03-12 2023-01-16 美商健生生物科技公司 經生物工程改造之免疫調節融合蛋白組成物
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
WO2024107749A1 (en) * 2022-11-16 2024-05-23 Attralus, Inc. Fusion proteins that bind amyloid and the transferrin receptor and uses thereof
WO2024193705A1 (en) * 2023-03-23 2024-09-26 Analytical Biosciences Shanghai Limited Tnf superfamily member immunocytokine and uses thereof
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762623A1 (en) * 1988-01-22 2007-03-14 ZymoGenetics, Inc. Methods for producing biologically active peptide dimers
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
EP0672141B1 (en) 1992-10-23 2003-05-14 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
NZ334035A (en) 1996-08-16 2000-09-29 Human Genome Sciences Inc Use of endokine alpha antagonists to diagnose and treat TNF-related disorders
US5998171A (en) 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
ES2320285T3 (es) 1997-11-18 2009-05-20 Genentech, Inc. Polipeptido dna19355, un homologo del factor de necrosis tumoral.
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
CA2321161C (en) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
DE10122140A1 (de) 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
AU2003270439B2 (en) 2002-09-11 2009-09-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
HUE039237T2 (hu) 2004-10-06 2018-12-28 Mayo Found Medical Education & Res B7-H1 és PD-1 vesesejt karcinoma kezelésében
WO2006050172A2 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
CA2606809C (en) 2005-05-06 2016-01-05 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
EP2399932B1 (en) 2005-05-12 2016-11-16 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
WO2007111931A2 (en) 2006-03-22 2007-10-04 Imperial Innovations Limited Compositions and methods relating to modulation of immune system components
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
NZ594510A (en) 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors
EP2009022A1 (en) 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
CA2692802C (en) 2007-07-10 2017-05-30 Oliver Hill Tnf superfamily collectin fusion proteins
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
US20090136446A1 (en) 2007-11-02 2009-05-28 Ludwig Institute For Cancer Research Ltd. Induction of regulatory t cell-resistant helper cd4+ t cells
JP5770624B2 (ja) 2008-04-09 2015-08-26 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
HRP20150425T1 (hr) 2008-07-21 2015-06-05 Apogenix Gmbh Tnf sf jednolanäśane molekule
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
SI2370593T1 (sl) 2008-11-28 2016-08-31 Emory University Postopek za določanje učinkovitosti antagonista pd-1
WO2010078966A1 (en) 2009-01-09 2010-07-15 Apogenix Gmbh Fusion proteins forming trimers
CN102421913A (zh) 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
PE20180042A1 (es) 2010-08-23 2018-01-09 Univ Texas Anticuerpos anti-ox40 y metodos de uso de los mismos
CA2831820C (en) * 2011-04-01 2021-05-25 Universitat Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
CA2874998A1 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
WO2013012733A1 (en) * 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
US20150073043A1 (en) 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
ES2740358T3 (es) 2012-02-06 2020-02-05 Providence Health & Services Oregon Método de supervisión del tratamiento del cáncer con agonistas de OX40
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
ES2848052T3 (es) 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
US10081759B2 (en) 2012-10-09 2018-09-25 Eric John Wernimont Method, apparatus, and composition for increased recovery of hydrocarbons by paraffin and asphaltene control from reaction of fuels and selective oxidizers in the subterranean environment
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2014106839A1 (en) 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
AU2014233114B2 (en) * 2013-03-15 2018-03-08 Richard S. Kornbluth Composition comprised of antigen linked to a TNF SuperFamily ligand
SG11201600310QA (en) 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
AU2014291961B2 (en) 2013-07-19 2018-09-27 Centre Hospitalier Regional Universitaire De Montpellier Targeted modified TNF family members
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
EP3161003A2 (en) 2014-06-27 2017-05-03 Apogenix GmbH Combination of cd95/cd95l inhibition and cancer immunotherapy
US9914761B2 (en) 2014-07-10 2018-03-13 Washington University Oligomers for TNF superfamily inhibition
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN106999594B (zh) 2014-11-11 2020-08-18 免疫医疗有限公司 用于治疗瘤形成的治疗组合
TWI757803B (zh) 2014-11-14 2022-03-11 瑞士商赫孚孟拉羅股份公司 包含tnf家族配位三聚體之抗原結合分子
WO2016112983A1 (en) 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
KR20180002653A (ko) 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
SG10201913807QA (en) 2015-07-23 2020-03-30 Inhibrx Inc Multivalent and multispecific gitr-binding fusion proteins
RU2018108236A (ru) 2015-08-12 2019-09-12 Медиммьюн Лимитед Слитые белки на основе gitrl и пути их применения
AU2016341402B2 (en) 2015-10-23 2020-08-27 Apogenix Ag Single-chain GITR-receptor agonist proteins

Also Published As

Publication number Publication date
WO2016126781A4 (en) 2016-10-13
CO2017008047A2 (es) 2018-01-05
WO2016126781A1 (en) 2016-08-11
BR112017016705A2 (pt) 2018-04-10
SG11201706268XA (en) 2017-08-30
IL253433A0 (en) 2017-09-28
EP3253890A1 (en) 2017-12-13
JP2018508233A (ja) 2018-03-29
US20180021407A1 (en) 2018-01-25
EA201791313A1 (ru) 2018-02-28
HK1243741A1 (zh) 2018-07-20
MA41460A (fr) 2017-12-12
PH12017501372A1 (en) 2017-12-18
CN107406878A (zh) 2017-11-28
EP3253890A4 (en) 2018-06-27
US10232017B2 (en) 2019-03-19
US9724390B2 (en) 2017-08-08
CN109180804A (zh) 2019-01-11
KR20170108073A (ko) 2017-09-26
TW201643184A (zh) 2016-12-16
US20160256527A1 (en) 2016-09-08
CA2975596A1 (en) 2016-08-11
AU2016215394A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
PH12017501372A1 (en) Tnfrsf-binding agents and uses thereof
MX2016014647A (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2024004017A (es) Proteinas de fusion de union a ox40 multivalentes y multiespecificas.
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
ZA202211577B (en) Multivalent and multispecific 41bb-binding fusion proteins
MX2018000948A (es) Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
IL267406A (en) Combined treatment of specific antibodies against cd20/cd3 and agonists of 4-1bb (cd137)
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
WO2017077085A3 (en) Immunomodulatory antibodies
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
IL253054A0 (en) Tumor necrosis factor superfamily receptor binding molecules and their uses
PH12018502502A1 (en) Anti-gitr antibodies and uses thereof
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
DK3253412T3 (da) Anti-cd40l-antistoffer og fremgangsmåder til behandling af cd40l-forbundne sygdomme eller forstyrrelser
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
MX2020005364A (es) Anticuerpos anti-ox40 y usos de los mismos.
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
WO2018144514A3 (en) Tnf superfamily fusion polypeptides